Breo ellipta and Erythromycin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Breo ellipta (fluticasone furoate; vilanterol trifenatate) and Erythromycin (erythromycin). Common drug interactions include diverticulum among females and cough among males.

The phase IV clinical study analyzes what interactions people have when they take Breo ellipta and Erythromycin. It is created by eHealthMe based on reports of 33 people who take the same drugs from the FDA, and is updated regularly.

What is Breo ellipta?

Breo ellipta has active ingredients of fluticasone furoate; vilanterol trifenatate. It is often used in asthma. eHealthMe is studying from 37,362 Breo ellipta users. Check the latest studies of Breo ellipta.

What is Erythromycin?

Erythromycin has active ingredients of erythromycin. It is often used in acne. eHealthMe is studying from 12,563 Erythromycin users. Check the latest studies of Erythromycin.

On Aug, 09, 2026

33 people who take Breo ellipta and Erythromycin together, and have interactions are studied.

Breo ellipta and Erythromycin drug interactions.

What are the common drug interactions of Breo Ellipta and Erythromycin, by gender? *:

female:

Diverticulum (out pouching of a hollow (or a fluid-filled) structure in the body)
Dyspnoea (difficult or laboured respiration)
Dysuria (painful or difficult urination)
Ear pain
Emphysematous pyelonephritis (presence of gas-producing bacteria in the kidney)
Epistaxis (bleed from the nose)
Eye discharge
Eye inflammation
Eye irritation
Eye pruritus (eye itching)

male:

Cough
Fatigue (feeling of tiredness)
Pneumonia
Productive cough
Urine output decreased
Weight increased
Adverse drug reaction
Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Arthritis (form of joint disorder that involves inflammation of one or more joints)

What are the common drug interactions of Breo Ellipta and Erythromycin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Discomfort
Drug ineffective
Rash
Sleep disorder due to a general medical condition

30-39:

Spinal fracture (fracture in one of vertebrae)
Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Bone density decreased
Depression
Emotional distress
Femur fracture
Foot fracture
Osteoarthritis (a joint disease caused by cartilage loss in a joint)
Osteoporosis (bones weak and more likely to break)

40-49:

n/a

50-59:

Adverse drug reaction
Arthritis (form of joint disorder that involves inflammation of one or more joints)
Autoimmune disorder (a condition in which the immune system attacks the body's normal substances and tissue)
Blood glucose decreased
Cough
Fatigue (feeling of tiredness)
Hypertension (high blood pressure)
Influenza
Infusion related reaction
Infusion site erythema (reddening of the skin at infusion site)

60+:

Pneumonia
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Colitis ischaemic (due to infection of intestine impaired blood supply to colon)
Essential hypertension (primary hypertension)
Fungaemia (fungi circulate in the blood)
Influenza
Infusion site pruritus (severe itching at infusion site)
Infusion site swelling
Intestinal ischaemia (decreased supply of oxygenated blood to the intestines)
Lung hyperinflation (inspiration of more than normal)

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 7 people, 21.21%
Neurotrophic Keratopathy (decreased corneal sensitivity and poor corneal healing): 6 people, 18.18%
Immunodeficiency Common Variable: 3 people, 9.09%
Ulcerative Keratitis (ulcerative inflammation of the cornea): 2 people, 6.06%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 2 people, 6.06%
Primary Immunodeficiency Syndrome: 2 people, 6.06%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 2 people, 6.06%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 2 people, 6.06%

* Approximation only. Some reports may have incomplete information.

Do you take Breo ellipta and Erythromycin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously